This Article Full Text (PDF) All Versions of this Article: 1352458509106509v1 15/8/913    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cénit, M. Articles by Martínez, A Search for Related Content PubMed PubMed Citation Articles by Cénit, M. Articles by Martínez, A Social Bookmarking                         What's this?

Glypican 5 is an interferon-beta response gene: a replication study

Clinical Immunology Department, Hospital Clínico San Carlos, Madrid, Spain;

F Blanco-Kelly

Clinical Immunology Department, Hospital Clínico San Carlos, Madrid, Spain;

V de las Heras

Multiple Sclerosis Unit, Hospital Clínico San Carlos, Madrid, Spain

M Bartolomé

Multiple Sclerosis Unit, Hospital Clínico San Carlos, Madrid, Spain

EG de la Concha

Clinical Immunology Department, Hospital Clínico San Carlos, Madrid, Spain

E Urcelay

Clinical Immunology Department, Hospital Clínico San Carlos, Madrid, Spain

R Arroyo

Multiple Sclerosis Unit, Hospital Clínico San Carlos, Madrid, Spain

A Martínez

Clinical Immunology Department, Hospital Clínico San Carlos, Madrid, Spain; alfmdoncel{at}gmail.com

Background

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Interferon-beta is the most usual therapy in relapsing-remiting MS. However, approximately 50% of the treated patients do not respond adequately. Very recently, a genome-wide association study on interferon-beta pharmacogenetics has described polymorphisms at several genes that are associated with response to this treatment. Our aim is to replicate the results obtained at the two loci most strongly implicated in the response to interferon-beta treatment, HAPLN1 and GPC5.

Patients and methods

We performed a case–control study, analyzing 199 patients with MS treated with interferon-beta for at least 2 years and at least two documented relapses over the 2 years, previous to treatment onset. Responders had neither relapses nor increase in expanded disability status scale (EDSS) over the 2-year follow-up period, whereas nonresponders had at least two relapses or an increase in EDSS of at least 1 point. We studied three single-nucleotide polymorphisms (SNPs) in the GPC5 locus and three SNPs in the HAPLN1 locus by TaqMan technology. Allelic frequencies between responders and nonresponders were compared by a chi-square test.

Results

An association was found between GPC5 polymorphisms and the response to interferon-beta therapy in patients with MS, in agreement with earlier data (responder vs nonresponder patients: rs10492503, P = 0.0005). The other locus studied (HAPLN1) did not show association with treatment response to interferon-beta (all SNPs P > 0.05).

Conclusions

We confirm the association of polymorphisms within GPC5 with response to interferon-beta therapy in patients with MS.

Key Words: GPC5 • HAPNL1 • interferon-beta treatment • multiple sclerosis

This version was published on August 1, 2009

Multiple Sclerosis, Vol. 15, No. 8, 913-917 (2009)
DOI: 10.1177/1352458509106509


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. J. Pappas and J. R. Oksenberg Multiple sclerosis pharmacogenomics: Maximizing efficacy of therapy Neurology, January 5, 2010; 74(1_Supplement_1): S62 - S69. [Abstract] [Full Text] [PDF]